Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
01:37pm, Wednesday, 26'th Mar 2025
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
06:47pm, Tuesday, 25'th Mar 2025
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they trad
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note
06:55pm, Monday, 24'th Mar 2025
In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
11:10am, Friday, 21'st Mar 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why the Market Dipped But Amgen (AMGN) Gained Today
06:56pm, Tuesday, 18'th Mar 2025
Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
12:50pm, Tuesday, 18'th Mar 2025
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Prediction: These 2 Stocks Will Outperform the Market Through 2030
09:53am, Tuesday, 18'th Mar 2025
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns.
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
07:05pm, Monday, 17'th Mar 2025
The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
01:05pm, Monday, 17'th Mar 2025
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 17'th Mar 2025
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing * Late-Breaking Data to be Presented at AAN 2025 THOUSAND OAKS, Calif. , March 13, 2025 /PRNewswire/ -- A
HALO vs. AMGN: Which Stock Is the Better Value Option?
12:40pm, Tuesday, 11'th Mar 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option f
Amgen: Riding The MariTide Of Monthly Weight Loss
04:46pm, Monday, 10'th Mar 2025
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism a
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
10:30am, Monday, 10'th Mar 2025
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus
07:36am, Monday, 10'th Mar 2025
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
